NZ547626A - Non-covalent inhibitors of urokinase and blood vessel formation - Google Patents

Non-covalent inhibitors of urokinase and blood vessel formation

Info

Publication number
NZ547626A
NZ547626A NZ547626A NZ54762601A NZ547626A NZ 547626 A NZ547626 A NZ 547626A NZ 547626 A NZ547626 A NZ 547626A NZ 54762601 A NZ54762601 A NZ 54762601A NZ 547626 A NZ547626 A NZ 547626A
Authority
NZ
New Zealand
Prior art keywords
urokinase
blood vessel
vessel formation
compounds
carbon atoms
Prior art date
Application number
NZ547626A
Inventor
Odile Esther Levy
Edwin L Madison
Joseph Edward Semple
Amir P Tamiz
Michael I Weinhouse
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US63748300A priority Critical
Priority to US09/733,645 priority patent/US6586405B2/en
Priority to EP20000126874 priority patent/EP1182207B1/en
Application filed by Wilex Ag filed Critical Wilex Ag
Priority to NZ547626A priority patent/NZ547626A/en
Priority to NZ538572A priority patent/NZ538572A/en
Publication of NZ547626A publication Critical patent/NZ547626A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C07K5/06069Ser-amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

Disclosed are compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation. The compounds are of formula I, wherein X is selected from SO2, NR'SO2, C=O, OC=O, NHC=O, POR' and a direct link, wherein R' is independently hydrogen, alkyl of 1 to about 4 carbon atoms, aryl of about 6 to about 14 carbon atoms or aralkyl of about 7 to about 16 carbon atoms, with the proviso that when X is POR' then R' is not hydrogen, and all other substituents are as described in the specification. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.
NZ547626A 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation NZ547626A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US63748300A true 2000-08-11 2000-08-11
US09/733,645 US6586405B2 (en) 2000-08-11 2000-12-07 Non-covalent inhibitors of urokinase and blood vessel formation
EP20000126874 EP1182207B1 (en) 2000-08-11 2000-12-07 Non-covalent inhibitors of urokinase and blood vessel formation
NZ547626A NZ547626A (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation
NZ538572A NZ538572A (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ547626A NZ547626A (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation

Publications (1)

Publication Number Publication Date
NZ547626A true NZ547626A (en) 2007-10-26

Family

ID=27223185

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ538572A NZ538572A (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation
NZ51819501A NZ518195A (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation
NZ547626A NZ547626A (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NZ538572A NZ538572A (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation
NZ51819501A NZ518195A (en) 2000-08-11 2001-08-10 Non-covalent inhibitors of urokinase and blood vessel formation

Country Status (6)

Country Link
JP (1) JP2004506648A (en)
AU (2) AU785260B2 (en)
CA (1) CA2387002A1 (en)
IL (1) IL149042D0 (en)
NZ (3) NZ538572A (en)
WO (1) WO2002014349A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364960A4 (en) * 2001-02-02 2005-05-18 Chugai Pharmaceutical Co Ltd Peptide derivatives
AU2002364713A1 (en) * 2001-12-04 2003-06-17 Corvas International, Inc. Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
DK1453852T3 (en) * 2001-12-12 2007-05-21 Wilex Ag Selective arylguanidine peptides as urokinase inhibitors
CA2478409C (en) 2002-03-11 2012-07-31 Curacyte Ag Inhibitors of urokinase, their preparation and use
DE10301300B4 (en) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Use of acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein
DE10323898A1 (en) 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
DE10342108A1 (en) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basic substituted benzylamine analogs as coagulation factor Xa inhibitors, their preparation and use
RU2410087C2 (en) 2005-06-24 2011-01-27 Вилекс Аг Urokinase inhibitors administration for treatment and/or prevention of neuropathological diseases
EP1919464A1 (en) * 2005-08-29 2008-05-14 Wilex AG Oxadiazole compounds as urokinase inhibitors
DE102005044319A1 (en) 2005-09-16 2007-03-22 Curacyte Chemistry Gmbh 2- (Aminomethyl) -5-chloro-benzylamide derivatives and their use as inhibitors of coagulation factor Xa
DE102006050672A1 (en) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations
GB0807828D0 (en) * 2008-04-29 2008-06-04 Vantia Ltd Aminopyridine derivatives
ES2483802T3 (en) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
AU1025795A (en) * 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
DE4443390A1 (en) * 1994-12-06 1996-06-13 Basf Ag New dipeptide p-Amidinobenzylamide with N-terminal sulfonyl or Aminosulfonylresten
BR9607412A (en) * 1995-02-10 1998-07-07 Basf Ag Thrombin inhibitor and the compound
US6576613B1 (en) * 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
EP1169338B1 (en) * 1999-04-09 2004-11-03 Abbott GmbH & Co. KG Low-molecular inhibitors of complement proteases
DE10029014A1 (en) * 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase inhibitor, useful for treatment, prophylaxis or diagnosis of thromboembolic disease, comprising acylated 3- or 4-amidino-benzylamine derivative
DE10029015A1 (en) * 2000-06-15 2001-12-20 Curacyte Ag Coagulation Factor Xa inhibitor, useful for treatment, prophylaxis or diagnosis of thromboembolic disease, comprising acylated 3- or 4-amidino-benzylamine derivative

Also Published As

Publication number Publication date
NZ538572A (en) 2006-09-29
JP2004506648A (en) 2004-03-04
CA2387002A1 (en) 2002-02-21
WO2002014349A3 (en) 2002-10-03
AU8334701A (en) 2002-02-25
AU2006235835A1 (en) 2006-11-30
AU785260B2 (en) 2006-12-07
IL149042D0 (en) 2002-11-10
WO2002014349A2 (en) 2002-02-21
NZ518195A (en) 2005-04-29
AU2006235835B2 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
TWI354666B (en) Heterocyclic aspartyl protease inhibitors
GEP20033130B (en) Inhibitors of IMPDH Enzyme
MXPA05001613A (en) Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity.
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
UA71945C2 (en) Substituted bicyclic derivatives being used as anticancer agents
MXPA02000294A (en) Prodrugs of carbamate inhibitors of impdh.
MY136039A (en) Sorbitol dehydrogenase inhibitors
BR0114253A (en) Metabotropic Glutamate Receptor Antagonists
NZ540381A (en) 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
HU0400992A2 (en) Carboxylic acid substituted oxazole derivatives, process for their preparation and their use as ppar-alpha and-gamma activators for the manufacture of pharmaceutical compositions in the treatment of diabetes
BR0317435A (en) Pyrimidine Derivatives for the Treatment of Abnormal Cell Growth
NZ527251A (en) Heterocyclic inhibitors of ERK2 and uses thereof
IL189383D0 (en) Derivatives of 4-piperazin-1-yl
MXPA00012443A (en) Epothilone derivatives and their synthesis and use.
RU94044343A (en) CATECHOLAMINE SUBSTITUTES SUITABLE AS β3-AGONISTS, INTERMEDIATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PROCESS FOR TREATING DISEASES
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
WO2005060963A8 (en) Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
WO2002011715A3 (en) The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
NZ539676A (en) Phenethanolamine derivative for the treatment of respiratory diseases
HK1101402A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MXPA06004006A (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease.
MY131995A (en) Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
CA2431160A1 (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
BRPI0413283A (en) (thio) carbamoyl cyclohexane derivatives as d3 / d2 receptor antagonists
NZ518886A (en) Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: WILEX AG, DE

Free format text: OLD OWNER(S): DENDREON CORPORATION

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)